HYperfractionated Radiation Therapy Versus Concurrent Chemoradiation for Head and Neck Cancer (HYTC)

This is an international multi-centre, non-inferiority phase III randomized controlled trial comparing concurrent chemoradiation with high dose cisplatin (Arm A) vs. hyperfractionated radiation therapy (Arm B) in patients with head and neck squamous cell carcinoma.

Trial Details

NCT ID
NCT07801235
Phase
NA
Sponsor
King Hussein Cancer Center
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • 70 gy 35 fractions/7weeks+high dose of cisplatin
  • 81.6 Gy /68 fractions BID FOR 7 WEEKS
Locations (sample)
  • Amman, Jordan|31.95522,35.94503

Key Eligibility Criteria

  • Diagnostic tonsillectomy or local excision of the primary without removal of nodal disease is permitted.
  • Diagnostic lymph node excision or limited neck dissections (retrieving ≤ 4 nodes) are permitted HPV positive or negative (by p16 immunohistochemist…
  • For patients with OPC: analysis of p16 status is required For patients with laryngeal/hypopharyngeal cancer: analysis of p16 status is NOT required
  • Clinical stage T1-2 N1-2 M0 or T3 N0-2 M0 (UICC/AJCC TNM 8th Edition). Staging will be determined based on clinical examination, axial imaging (CT …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →